With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.127956-11-0,Methyl 4-oxotetrahydro-2H-pyran-3-carboxylate,as a common compound, the synthetic route is as follows.
To a solution of methyl 4-oxotetrahydro-2H-pyran-3-carboxylate (51.1 g, 323 mmol) and benzyl 2-amino-2-iminoethylcarbamate hydrochloride (78.8 g, 323 mmol) in anhydrous ethanol was added sodium ethoxide (122 mL, 323 mmol, 21 % in ethanol). The mixture was mechanically stirred, heated at reflux for 24 h, cooled down to ambient temperature, and filtered to give the title compound (55.6 g, 55% yield). 1 H NMR (400 MHz, DMSO- d6) delta 12.40 (br. s., 1 H), 7.69 (t, J=5.8 Hz, 1 H), 7.15 – 7.44 (m, 5 H), 4.99 – 5.08 (m, 2 H), 4.35 (s, 2 H), 4.04 – 4.1 1 (m, 2 H), 3.84 (t, J=5.3 Hz, 2 H), 2.48 – 2.57 (m, 2 H). MS m/z 316.2 (M+1 ), retention time = 1.10 min.
As the paragraph descriping shows that 127956-11-0 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; CHEUNG, Atwood, Kim; CHIN, Donoval, Noel; FAN, Jianmei; SHULTZ, Michael, David; TOMLINSON, Ronald, Charles; WO2013/10092; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics